Skip to main content

fosfomycin

Generic: FOSFOMYCIN TROMETHAMINE·Brand: CONTEPO, Contepo, FOSFOMYCIN TROMETHAMINE, MONUROL

fosfomycin: developed by 1 company · 1 FDA decision.

fosfomycin evidence translation

What we can confirm

What it means

Source-backed records connect fosfomycin to DTIL; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could fosfomycin → DTIL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (1)
CompanyPhase
PRECISION BIOSCIENCES INC (DTIL)Approved
FDA Decisions1 records
ApprovalINDICATIONS AND USAGE Fosfomycin Tromethamine is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin Tromethamine Granules for Oral Solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with Fosfomycin Tromethamine, other therapeutic agents should be selected. (Se(DTIL)FDA ↗
ANDA217187UNKNOWNStandardOralFor Solution

Frequently asked questions

Who is developing fosfomycin?

fosfomycin is being developed by PRECISION BIOSCIENCES INC.

What is fosfomycin's latest FDA decision?

The most recent tracked FDA decision for fosfomycin is Approval for INDICATIONS AND USAGE Fosfomycin Tromethamine is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin Tromethamine Granules for Oral Solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with Fosfomycin Tromethamine, other therapeutic agents should be selected. (Se, dated June 3, 2025.